Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-AMG211 PET Imaging in GI Adenocarcinoma
NCT02760199Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2016
- Primary completion
- May 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-AMG211 in gastrointestinal adenocarcinoma (GIAC), sponsored by University Medical Center Groningen. Primary endpoint: Standardized Uptake Value at 1 year. Started Aug 2016; status: completed.
02
Drugs
89Zr-AMG211
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NCT02760199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760199.